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Beta-Adrenergic Blocking Agents After Myocardial Infarction: An
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THOMAS R. GRIGGS, MD, GALEN S. WAGNER, MD, FACC, LEONARD S. GETTES, MD, FACC
Chapel Hill and Durham, North Carolina
The recently published Beta-Blocker Heart Attack Trial
(BHA T) study (1) and the European studies of the last 7
years (2-5) clearly indicate that the administration of ap-
propriate doses of a beta-adrenergic blocking drug is as-
sociated with reduced late mortality after acute transmural
myocardial infarction (Fig. 1 and 2). Such a drug is reported
to prevent reinfarction and to reduce the lethal complications
in those who, in spite of the medicine, develop a coronary
ischemic event. It is not clear if these two effects are related,
and the mechanisms underlying these effects are not well
understood. One probable mechanism is that the drugs pre-
vent ventricular fibrillation. This mechanism is consistent
with the findings of a large number of studies performed
since 1951 indicating that unilateral sympathectomy or the
administration of beta-adrenergic blocking agents prevents
ventricular fibrillation after acute coronary occlusion in an-
imal models (6-11). Thus, while it is not surprising that
beta-adrenergic blocking drugs are capable of altering the
natural history of ischemic heart disease, it is surprising that
so many years and so many patients were required before
this effect could be documented.
Identification of low risk patient group after acute
myocardial infarction. A possible reason for the delay in
the documentation of the effectiveness of beta-adrenergic
blocking agents in preventing mortality is that the patients
at highest risk were specifically excluded from entry into
the studies. Thus, the study populations undoubtedly in-
cluded a significant number of patients at low risk. It has
been obvious for years that a considerable proportion of
patients do very well after an acute myocardial infarction,
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especially those who survive beyond the first 6 months.
Numerous studies have demonstrated that the absence of a
previous myocardial infarction, normal left ventricular func-
tion, freedom from ventricular arrhythmia and an inferior
rather than an anterior wall infarct identified patients at low
risk for subsequent sudden death. Several methods have
been used to further classify the patients into various risk
categories. These include the predischarge exercise toler-
ance test (12,13) and extended, ambulatory electrocardio-
graphic monitoring (14,15). The results obtained using these
techniques have permitted the identification of patients who
have a 1 year mortality rate of no more than 2% and a
projected 3 year cumulative mortality rate of about 6%.
These mortality figures are little different from those of the
total population of patients with known coronary heart dis-
ease and are only slightly increased when compared with
the "prognosis" of unclassified or normal populations of
equal age. It is possible that no intervention would signif-
icantly improve the survival of these low risk patients. The
recognition of this possibility permits a challenge to the
recommendation of the BHAT study that every patient who
has had a recent myocardial infarction and in whom no
contraindication exists should receive a beta-blocking age~t
for 3 years starting during the immediate postmyocardial
infarction period.
The most striking demonstration of a low risk group was
reported by Weld et al. (12). Their study included 250
patients, 236 of whom were subjected to a low level exercise
test before discharge from the hospital after a myocardial
infarction. Total mortality after 1 year was 12%. However,
47% of the patients were able to exercise for 9 minutes
without developing ST segment depression or premature
ventricular beats. In this group, the 1 year mortality rate
was only 1%.
Theroux et al. (13) used a low level exercise test to study
210 postmyocardial infarction patients. The 1 year mortality
rate among the total group was 9.5%. However, more than
half of the patients had neither chest pain nor ST segment
depression during the test. The I year mortality was 2.1 %
in those patients.
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Figure 2. Total (T) andcumulative (C) mortality among patients
intheBHATpropranolol (Pr) study (I), theNorwegian multicenter
timolol (Tm) study (2) and themetoprolol (Mt) study (3). Patients
receiving placebo are shown by the hatched bars; patients re-
ceiving theexperimental medication are shown by theopen bars.
(2), and the BHAT study, which employed propranolol (I),
the patients were separated into three relative risk groups
(Fig. I). Group I in both studies comprised patients who
had previously had a myocardial infarction. Group II in the
timolol study included patients with no previous myocardial
infarction and one of the following conditions: I) transient
left ventricular failure, 2) cardiomegaly by chest X-ray film,
3) atrial fibrillationor atrial flutter, 4) transient hypotension,
and 5) serum aspartate amino transferase levels exceeding
four times the upper limit of normal. In the BHAT study,
the patients in Group II were those with complications dur-
ing the hospitalization, including heart failure, pulmonary
edema, cardiogenic shock, persistent hypotension, ventric-
ular fibrillation, atrial fibrillation or heart block.
In both studies, the Group III patients had none of the
complications listed in Groups I and II and could then be
considered at low risk. The mortality in each of the Group
III subgroups was presented as total mortality, that is, total
deaths divided by the number of patients in each group,
rather than as cumulative mortality. However, cumulative
mortality can be estimated from the figures given for the
total population included in the timolol and BHAT studies.
The cumulative mortality rate for the placebo-treated pa-
tients in the combined subgroups was 17.5% in the timolol
study and 13.3% in the BHAT study (Fig. 2). The respective
total mortality rate in these groups (total deaths divided by
the total number of patients) was 12 and 8.5%. Therefore,
the cumulative mortality was approximately 1.5 times the
total mortality. The reported total mortality rate in the pla-
cebo-treated Group III patients was 7.3% in the BHAT study
and 5.4% in the timolol study. If these figures are adjusted
for cumulative mortality by multiplying by 1.5, possible 3
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Using a different analytical system, Moss et al. (14) and
Davis et al. (15) also identified a group of patients with a
very low mortality rate after myocardial infarction. These
investigatorsexamined 940 patients during a 12 to 60 month
follow-upperiod. Among this group, there were 115deaths,
a total mortality rate of 12.2%. They identified a subset of
patients with no history of previous myocardial infarction,
no clinical evidence of left ventricular dysfunction and no
premature ventricular beats on a 6 hour ambulatory electro-
cardiographic monitor (Fig. 3). In this subset, which com-
prised 24% of the total study population, the I year mortality
rate was 1.5% and the 3 year cumulative mortality rate was
6%. Taken together, these several studies indicate that 25
to 50% of patients who survive an acute myocardial in-
farction have a risk of dying of approximately I to 2% per
year.
Analysis of risk groups in the BHAT and Norwegian
studies. Effort was made in several of the beta-blocker
trials to divide the patients into groups according to known
risk factors. However, none of the trials used ambulatory
electrocardiographic monitoring or exercise testing. Thus,
it is likely that even the "low risk" groups described in
these beta-blocker trial studies contained patients whose risk
of dying was higher than that of the patients at lowest risk
identified in the studies described previously. In the Nor-
wegian Multicenter Study Group, which employed timolol
Figure 1. Cardiac mortality among the patients In the BHAT
(propranolol) (I) andNorwegian (timolol) (2) studies. The patients
were classified into-three prognostic groups (Groups L II and III)
according to the criteria descnbed in the text. The total mortality
is reflected by the height of the bars. Patients receiving placebo
are shown bythehatchedbars; those receiving thetrial medication
are shown by the open bars. The numbers inside the bars are the
total number ofpatients inthat group. The differences (6) between
placebo and treatment groups are shown above the bars.
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References
ment in survival from the use of the drug. Further, in the
BHAT study, the individual patient groups were not sub-
jected to statistical analysis. However, there was a trend
toward better survival in treated groups in each study. As-
suming that this trend was genuine, we are left with the
conclusion that the benefit was predominantly manifest among
those patients who would have been excluded from a "low-
est risk" category had predischarge screening with exercise
testing or ambulatory monitoring been used. This is the most
attractive possibility, because the mortality rate among pa-
tients with normal exercise tolerance, normal ventricular
function and the absence of ventricular arrhythmias is so
low that it is unreasonable to expect any medication to
improve survival in a statistically significant fashion,
Therapeutic implications. Obviously, this is an issue
that should be addressed by new studies. In the meantime,
should we feel obligated to treat the patients who are clearly
shown to be in the category at lowest risk? Stated another
way, should the failure to administer these drugs to those
in the group at lowest risk be considered less than optimal
therapy? One might argue that evert though the benefit of
the drugs in the patients at lowest risk is not proved, there
is little evidence of serious short-term side effects from the
drugs. Yet, there is always the possibility that an unanti-
cipated problem with one of the drugs may arise, as was
the case with practolol (16). Second, the monetary cost of
the medication and the possible toll of "benign" side ef-
fects, such as fatigue or depression, cannot be dismissed.
Treatment, in other words, is not without some actual and
potential cost.
Until these questions have been resolved, it would seem
reasonable to use individual judgment on a patient by patient
basis, Considerable effort should be made to define the
prognosis in every patient. Among the most promising non-
invasive methods for this assessment are the exercise test,
ambulatory electrocardiographic monitoring and radio-
nuclide ventriculography. Additionally, it is possible that
the predischarge 12 lead electrocardiogram will provide a
reasonable estimate of left ventricular function (17) that can
be used when radionuclide studies are not available. It is
our opinion that when these tests identify a patient with
good exercise tolerance, normal left ventricular function and
no ventricular arrhythmia, the need to use a beta-adrenergic
blocking agent is not documented and should not be con-
sidered obligatory at this time.
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year mortality rates of 11 and 8% are obtained, These rates
are considerably higher than the 6% cumulative mortality
rate in those at lowest risk identified by Moss et al, (14,15),
Thus, the Group III patients in the beta-blocker studies
undoubtedly included patients who would have been ex-
cluded from the group at lowest risk if the screening tech-
niques used in the risk factor studies had been employed,
Therefore, the following statements appear justified: 1)
Twenty-five to 50% of all patients surviving an acute myo-
cardial infarction fall into the group at "lowest risk" as
defined by the studies of Weld et al. (12), Theroux et al.
(13) and Moss and Davis et al. (14,15). 2) The Group 1lI
patients in the BHAT and Norwegian studies must have
included the patients at lowest risk as defined above. 3) The
group at lowest risk must have constituted 50% or more of
the Group III patients.
Do the beta-blocker trial studies show a reduced mor-
tality? If it is true that a large proportion of patients in-
cluded in the beta-blocker studies were at very low risk,
how could treatment of this group with beta-adrenergic
blocking agents be shown to reduce mortality? First, it is
not obvious that a reduction in mortality has been shown,
In the timolol study, the patients in Group 1lI were specif-
ically shown not to derive a statistically significant improve-
70
Figure 3. Cumulative survival among Group 1Ilpatients (patients
with other than anterior infarcts) with no prior myocardial infarc-
tion in the studies of Davis et al. (15), LVD = left ventricular
dysfunction defined as evidence on X-ray film or physical ex-
amination of pulmonary edema or congestive heart failure during
the immediate postinfarction period while the patient was in the
coronary care unit; VPD = one or more premature ventricular
depolarizations on 6 hour ambulatory electrocardiographic moni-
toring done before discharge after the acute infarction,
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